Takeaways from the most recent news in the technology and policies shaping healthcare.
The money moving through health tech: venture rounds, M&A, IPOs, and the financial health of the companies and systems behind care.
CMS finalized fiscal 2027 payment rules giving inpatient rehabilitation facilities and hospices each a 2.3% payment increase.
Why it matters: Thin Medicare increases set the revenue baseline for rehab and hospice operators already squeezed by labor and supply costs.
Crystalys Therapeutics raised $130 million to advance its URAT1 inhibitor dotinurad through pivotal gout trials.
Why it matters: Fresh capital and a $950M Sobi deal show pharma is finally targeting gout, a common condition with few effective treatment options.
Hospital operating margins fell 5% nationally in early 2026, deepening a profitability divide between smaller hospitals and large nonprofit systems.
Why it matters: A widening margin gap determines which hospitals can invest, consolidate, or survive, reshaping access and competition across the industry.
Health system CFOs are shifting from cost-cutting to revenue integrity, payer negotiation and AI-assisted reporting to sustain margins, per Becker's.
Why it matters: Hospital margins remain thin, and where CFOs invest next shapes which vendors, technologies and strategies win healthcare dollars.
An Indiana hospital credits a switch in its employee health insurance with generating savings it used to expand patient services, amid a broader employer exodus from costly traditional group plans.
Why it matters: Health systems are large employers too, and how they manage their own insurance costs shapes both their finances and the services patients can access.
New Tavern Research polling shows Medicare for All support swings nearly 20 points depending on wording, amid ACA strain and rising employer costs.
Why it matters: Voter opinion on single-payer reform is soft and framing-dependent, which will shape the political viability of any future overhaul of how Americans get coverage.
Providers are using AI to monitor payer contracts continuously, catching underpayments and denials that erode margins long after negotiations end.
Why it matters: Underpayments and denials quietly drain provider margins, and continuous contract monitoring is becoming a core revenue cycle defense.
Hospital operating margins rose slightly in April but remained behind 2025 levels as expense growth outpaced inflation, per Kaufman Hall's latest report.
Why it matters: Thin, lagging margins limit how much hospitals can invest in staffing, technology, and care, even as patient volumes recover.
At least 24 health systems are dropping select Medicare Advantage plans for 2026 over prior authorization and reimbursement disputes, putting senior patient access at risk.
Why it matters: As Medicare Advantage covers most US seniors, provider exits can strip patients of in-network access to their hospitals and doctors.
Becker's ranking of 104 health systems by revenue shows broad 2025 gains fueled by volumes, pricing, ambulatory and pharmacy expansion, with M&A driving the biggest outliers.
Why it matters: Revenue scale and consolidation increasingly determine which health systems can invest, negotiate, and compete.
Employers are increasingly bypassing broad provider networks for ICHRA, reference-based pricing and direct contracting, eroding a structure that has defined payer-provider deals for decades.
Why it matters: As employers route around broad networks, hospitals lose negotiating leverage and face new pressure on pricing and patient volume.
Healthcare systems are scaling AI beyond pilots and using it to close revenue gaps through smarter coding, documentation, and denial management.
Why it matters: Revenue cycle automation is emerging as healthcare AI's clearest path to measurable financial return amid reimbursement and labor pressure.
The Medicare Hospital Insurance Trust Fund will fund full Part A benefits only through Q2 2033, a quarter earlier than projected, with Medicare Advantage spending cited as a strain.
Why it matters: An earlier depletion date raises the stakes on Medicare reimbursement and intensifies scrutiny of Medicare Advantage costs that providers depend on.
AstraZeneca's oral GLP-1 drug showed promise in mid-stage obesity and diabetes trials, but its standing against rival pills remains unclear.
Why it matters: An effective GLP-1 pill could broaden access to weight-loss and diabetes treatment and intensify competition in a market headed past $100 billion.
Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.
Why it matters: The deal shows how biopharma companies race to backfill pipelines and diversify ahead of major patent cliffs.
GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.
Why it matters: The deal shows how big drugmakers are spending billions on precision oncology to refill pipelines ahead of patent cliffs.
Gilead and Merck reported one trial win and one failure the same week, as AstraZeneca advanced a GLP-1 pill and GSK announced a $10.6 billion cancer acquisition.
Why it matters: Late-stage trial outcomes and multibillion-dollar deals from pharma's biggest players shape which therapies reach patients and where investor capital flows.
GSK will acquire Nuvalent for $10.6 billion, gaining two near-commercial precision drugs for non-small cell lung cancer that are now under FDA review.
Why it matters: The deal underscores how big pharma is paying premium prices for late-stage precision oncology assets to refill pipelines and accelerate revenue.
R1 RCM named former Humana CTO Eric Tagliere as chief information officer to lead its global technology organization.
Why it matters: R1 processes billing for many U.S. health systems, so its technology leadership shapes how providers get paid amid mounting margin pressure.